Hormone replacement therapy is one of the most underserved and fastest-growing categories in cash-pay telehealth. Millions of women in perimenopause and menopause are actively seeking treatment, the clinical evidence for HRT has dramatically improved over the past decade, and a generation of direct-to-consumer brands has demonstrated strong demand for accessible, subscription-based programs.
For Entrepreneurs, Creators, and Clinic Owners, this creates a substantial opportunity: a large addressable market, a recurring-revenue business model, and a patient population with long retention and high lifetime value.
This guide covers everything you need to understand before launching an HRT telehealth brand: the market opportunity, how compounded bioidentical hormones work, how the business model functions, what you need to get started, the economics, and the regulatory landscape you need to operate within.
The HRT Market Opportunity
The scale of unmet demand for hormone therapy is significant.
Approximately 1.3 million women in the United States enter menopause every year, according to data from the North American Menopause Society. The perimenopausal transition typically begins in the mid-40s, meaning the total addressable population of symptomatic women is in the tens of millions at any given time.
Despite this scale, most women receive no treatment. A combination of factors created an enormous gap:
- The 2002 Women’s Health Initiative study generated significant controversy about HRT safety and led to a steep decline in prescribing that lasted nearly two decades
- Primary care physicians spend an average of less than 2 hours on menopause education during medical school and residency, according to research published in Menopause
- Insurance coverage for hormone therapy is inconsistent and many patients prefer cash-pay for privacy and simplicity
The result is a large, motivated patient population with disposable income actively searching for competent providers willing to prescribe modern HRT protocols. Telehealth brands like Alloy, MIDI Health, Evernow, and Caria have demonstrated that this population converts well through digital channels.
The clinical narrative has also shifted. Comprehensive reviews and the NAMS 2022 Hormone Therapy Position Statement now affirm that HRT benefits outweigh risks for most healthy women under 60 who are within 10 years of menopause onset. This evidence base makes HRT easier to discuss, prescribe, and market appropriately.
Understanding Compounded Bioidentical Hormones
What Bioidentical Means
Bioidentical hormones are identical in molecular structure to the hormones naturally produced by the human body. The most clinically relevant distinction is between bioidentical progesterone and synthetic progestins like medroxyprogesterone acetate (MPA), which differ in molecular structure and have different receptor binding profiles.
Compounded bioidentical HRT uses pharmaceutical-grade APIs manufactured by licensed compounding pharmacies. The formulations are not FDA-approved finished drug products, but the underlying molecules (estradiol, progesterone, testosterone) are well-characterized and widely used in both compounded and FDA-approved form.
Common Medications in HRT Programs
Estradiol (Estrogen)
Estradiol is the primary estrogen used in HRT programs. It is available in multiple delivery methods, each with distinct pharmacokinetics and patient preferences:
- Transdermal cream or gel: Applied daily to thin-skinned areas (inner arm, inner thigh). Compounded at custom strengths. Avoids first-pass liver metabolism, which is clinically relevant for cardiovascular risk.
- Sublingual troche: Placed under the tongue for rapid absorption. Popular with patients who prefer not to apply cream.
- Oral capsule: Convenient but undergoes first-pass metabolism; requires higher doses for equivalent systemic effect.
- Vaginal formulations: Low-dose estriol or estradiol used specifically for genitourinary symptoms without significant systemic absorption.
Progesterone
Progesterone is prescribed alongside estradiol for women with an intact uterus to protect the endometrium. Compounded bioidentical progesterone is functionally equivalent to FDA-approved oral progesterone (Prometrium) and is available as:
- Oral capsule: Most common. Taken at bedtime due to sedating effect.
- Transdermal cream: Lower systemic absorption than oral; sometimes used for women with digestive sensitivity.
- Sublingual troche: Higher systemic absorption than cream.
Testosterone for Women
Low-dose testosterone is increasingly incorporated into women’s HRT protocols to address libido, energy, cognitive function, and mood. Compounded at doses approximately 10x lower than male TRT programs:
- Transdermal cream: Typical compounded concentration 1% to 2%, applied to inner thigh or labia.
- Sublingual troche: Alternative delivery for patients who prefer not to apply cream.
DHEA and Estriol
DHEA (dehydroepiandrosterone) is sometimes added to support adrenal hormone production. Estriol, a weak estrogen, is used in vaginal formulations and in some practitioners’ systemic protocols.
Compounded vs FDA-Approved HRT
| Factor | Compounded Bioidentical | FDA-Approved HRT |
|---|---|---|
| Formulation flexibility | High (custom doses, delivery methods) | Fixed doses, standard formulations |
| Insurance coverage | None | Possible |
| Monthly cash-pay cost | $80-$180 | Varies widely |
| Personalization | Customizable per patient | Limited |
| Quality oversight | 503A/503B pharmacy standards | FDA-regulated cGMP |
Compounded HRT is the commercial backbone of most cash-pay HRT programs because it allows custom dosing and delivery methods, at a price point that works for patients, with the flexibility to adjust formulations as patients are optimized.
Who Your Patients Are
Understanding the patient population shapes everything from marketing to protocol design.
The Perimenopausal Patient
Perimenopause typically begins in the mid to late 40s and can last 4 to 8 years. Symptoms include irregular cycles, hot flashes, night sweats, sleep disruption, mood changes, brain fog, weight gain, and decreased libido. Many perimenopausal women have normal or only slightly irregular hormone levels on testing, which makes diagnosis clinical rather than purely lab-based.
This patient is often frustrated by primary care providers who attribute symptoms to stress or aging. She has done her own research, knows what she wants, and is willing to pay cash.
The Postmenopausal Patient
Postmenopause begins 12 months after the final period. Estrogen levels have dropped substantially. Symptoms include persistent vasomotor symptoms, vaginal dryness, joint pain, cardiovascular risk changes, and bone density loss. These patients have clear lab findings that support HRT and are often the highest-retention cohort because their need for therapy is definitive.
The Surgical Menopause Patient
Women who have undergone oophorectomy experience immediate surgical menopause, often at younger ages than natural menopause. This population has the strongest clinical indication for HRT and the longest potential treatment duration.
Marketing Channels That Work
HRT patients are reachable through:
- Meta advertising: Women 40-60 respond well to symptom-focused creative and educational content
- Organic search and content: High-volume searches for “perimenopause symptoms,” “bioidentical hormones,” and “HRT telehealth” represent bottom-of-funnel intent
- Podcast advertising: Health and wellness podcasts with female audiences in the 40s-50s demographic convert well
- Influencer partnerships: Female health and longevity creators with audiences in the perimenopause demographic can drive qualified patient referrals
The Business Model: How HRT Programs Make Money
An HRT telehealth program is a subscription healthcare business. Revenue flows from monthly program fees paid by patients on ongoing therapy.
The basic model:
- Patient acquisition through digital advertising, SEO, referrals, or existing practice relationships
- Intake completion: Patient completes a health history questionnaire, symptom assessment, and lab review
- Provider Review: A licensed Provider evaluates the patient’s Intake and, if appropriate, issues a prescription for an individualized HRT protocol
- Pharmacy fulfillment: A compounding pharmacy prepares the customized formulation and ships directly to the patient
- Monthly subscription: The patient pays a recurring fee that covers the medication, Provider access, and ongoing management
- Renewal and monitoring: Labs are repeated at intervals; the Provider adjusts the protocol as needed; the patient remains on a monthly subscription
Optional Revenue Layers
Programs can add revenue through:
- Comprehensive hormone panels: Initial and follow-up lab panels charged at cash-pay rates or included in premium tiers
- On-demand provider messaging: Patients pay for asynchronous provider access beyond standard check-ins
- Pellet therapy: Testosterone and estradiol pellets implanted subcutaneously every 3 to 6 months. Premium-priced ($400 to $800 per insertion visit) and in-person delivery only. Strong add-on for Clinic Owners with physical locations.
- Complementary programs: HRT patients are excellent candidates for GLP-1 weight loss, peptide therapy, and skin care programs
- Supplement subscriptions: Magnesium, collagen, adaptogens, and other supplements commonly used alongside HRT
What You Need to Launch
Four core components are required to operate an HRT telehealth program. None require a medical license.
1. A Clinical Platform
You need software to manage patient Intake, Eligibility Screening, Provider workflows, prescription routing, and ongoing communication. Building this from scratch is expensive. White-label platforms come pre-built with HRT-specific intake questionnaires, clinical decision support, and pharmacy integrations.
2. A Prescribing Network
Every prescription must be issued by a licensed Provider. If you are not a clinician, you need access to a prescribing network covering all states where you plan to serve patients. A 50-state network removes geographic limitations entirely.
3. A Compounding Pharmacy Partner
Your pharmacy partner prepares patient-specific hormone formulations and ships directly to patients. Key criteria for HRT pharmacy partners:
- PCAB (Pharmacy Compounding Accreditation Board) accreditation is a strong quality signal
- Third-party potency and sterility testing with certificates of analysis available
- Experience with hormone formulations specifically (not all compounding pharmacies specialize in this)
- Direct-to-patient shipping with appropriate temperature controls
- Licensed in the states where your patients are located
4. A Patient Acquisition Strategy
Paid digital advertising is the primary acquisition channel for most HRT programs. HRT patients search actively for solutions, which means SEO and content marketing also deliver qualified leads at lower cost than paid. Referral programs and influencer partnerships add acquisition volume without proportional cost increases.
Economics: Revenue Model and Patient LTV
Sample Program Economics
Assume a program price of $220 per month for a standard HRT subscription (estradiol plus progesterone, compounded, with provider access and annual lab review).
At a monthly churn rate of 4% (HRT patients are highly retained once stabilized), average patient lifetime is approximately 25 months. At $220 per month, average patient lifetime value is approximately $5,500.
If you are acquiring patients at $180 per patient, your payback period is under one month and your return on acquisition spend is over 30x over the patient lifetime.
Scale Economics
| Monthly Active Patients | Monthly Revenue | Annual Revenue |
|---|---|---|
| 100 | ~$22,000 | ~$264,000 |
| 250 | ~$55,000 | ~$660,000 |
| 500 | ~$110,000 | ~$1,320,000 |
| 1,000 | ~$220,000 | ~$2,640,000 |
These projections assume a single $220/month plan with 4% monthly churn. Real programs have plan tiers, higher-priced add-ons, and varying churn rates. The core dynamic holds: HRT is a high-retention, recurring-revenue model where scale compounds quickly.
Key Metrics to Track
- Monthly Recurring Revenue (MRR): Total active subscriptions per month
- Patient Acquisition Cost (PAC): Total marketing spend divided by new patients acquired
- Monthly Churn Rate: Percentage of active patients who cancel each month
- Patient Lifetime Value (LTV): Average revenue per patient over their full retention period
- LTV:PAC Ratio: Target 3:1 or higher for a sustainable program
Regulatory Landscape
FDA and Compounding Pharmacy Rules
Compounded bioidentical HRT operates primarily under Section 503A of the Federal Food, Drug, and Cosmetic Act. Unlike compounded GLP-1 medications, which are tied to drug shortage status, compounded hormones in custom formulations are not generally considered copies of specific FDA-approved products. This gives compounded HRT a more stable legal footing.
The FDA has published guidance on bulk drug substances used in compounding. Estradiol, progesterone, and testosterone are well-established APIs with long regulatory histories. Work with pharmacies that maintain current compliance documentation and can demonstrate their quality testing practices.
Telehealth Prescribing
HRT prescriptions can be issued via telehealth in most states. Unlike testosterone in male TRT programs (a Schedule III controlled substance), estradiol and progesterone are not controlled substances, which simplifies telehealth prescribing significantly. However, state-specific telehealth consent requirements and prescribing restrictions vary. Your prescribing network should maintain current state-by-state compliance documentation.
HIPAA Compliance
Any platform processing patient health information must comply with HIPAA. This includes Intake forms, communication tools, lab result workflows, and any advertising pixels on patient-facing pages. Ensure Business Associate Agreements are in place with all technology and pharmacy partners. For a deeper review of HIPAA requirements in cash-pay programs, read our HIPAA compliance guide for cash-pay medication programs.
Advertising and Health Claims
The FTC regulates health claims in advertising. For HRT programs, avoid unsubstantiated outcome promises and ensure all efficacy claims are grounded in peer-reviewed evidence. Reference organizations like NAMS or the Endocrine Society when citing clinical support for HRT. Review the FTC’s health products compliance guidance before running paid campaigns.
How to Build for Retention
HRT programs live or die on patient retention. The clinical evidence strongly supports long-term therapy, which means the primary retention driver is patient experience, not clinical need.
High-retention HRT programs consistently do three things:
1. Set expectations before symptoms resolve. Patients starting HRT often expect rapid relief. Transdermal estradiol takes 2 to 4 weeks to achieve steady-state levels. Patients who are not prepared for this timeline sometimes cancel before experiencing benefit. Clear onboarding communication reduces this early dropout window significantly.
2. Offer protocol adjustability. Hormone optimization is not a one-size-fits-all process. Patients who feel unheard when their initial protocol is not working will leave. Programs with proactive check-ins at 4 to 6 weeks and a clear process for requesting dose adjustments retain patients at dramatically higher rates.
3. Build the multi-program relationship. HRT patients over 40 frequently have concurrent health goals: weight management, skin health, energy, cognitive performance. Programs that introduce complementary offerings (peptides, GLP-1, compounded skincare) over time increase revenue per patient and deepen the relationship, making cancellation less likely.
Launch Checklist
Use this checklist to track your HRT program launch:
- Define your program scope (which hormones, delivery methods, tier structure)
- Confirm Provider coverage (own Provider or Provider Network)
- Select and contract with a compounding pharmacy specializing in hormone formulations
- Set up patient Intake forms specific to HRT (symptom assessment, medical history, contraindications)
- Establish lab ordering workflow (patient-directed or integrated)
- Create informed consent documentation
- Set pricing and program tiers
- Build HIPAA-compliant patient communication workflows
- Define onboarding protocol (initial consult, 4-week check-in, 3-month follow-up)
- Launch patient acquisition campaigns targeting perimenopausal and postmenopausal demographics
How Karpa Health Helps You Launch
Karpa Health provides the complete infrastructure for launching and scaling an HRT telehealth program. The Platform includes white-label patient Intake, a 50-state Provider Network, integrated Pharmacy Integration, Fulfillment, and the practice management tools needed to run a compliant, scalable program.
You bring the brand and the patients. Karpa Health provides the clinical and operational backbone.
Whether you are a Creator building a women’s hormone health brand, an Entrepreneur entering women’s health from outside medicine, or a Clinic Owner adding HRT to an existing practice, the Platform is designed to remove the barriers between your business vision and a live, revenue-generating program.
For more on how the Platform works, explore the entrepreneur program or the clinic owner program.
For related context, read our guides on starting a TRT program, telehealth prescribing compliance, and the cash-pay revenue model for hormone programs.
Start your HRT brand if you are ready to launch with Karpa Health.
